Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis

Novartis Media Relations

Media only:

Investors only:

Gloria Vanderham

Richard Jarvis

Novartis Oncology

Novartis Corporation

P: +1 862 778 4268

P: +1 212 830 2433

Dana Kahn Cooper

[email protected]

P: +1 732 817 1800

F: +1 732 817 1834